LENZ Therapeutics, Inc. (LENZ): who owns it and who trades it
As of Nov 16, 2026, LENZ insiders reported 5 open-market sales worth $9.4M and 3 purchases worth $366K in the last 12 months, with 3% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ra Capital Management, L.P. (10% owner), with $9.1M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling LENZ Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LENZ
144 funds and institutions reported LENZ shares worth $198M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 13.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 4.18M | 13.33% | $23.7M | No change |
| Alpha Wave Global, LP | 3.61M | 11.52% | $20.5M | No change |
| FMR LLC (Fidelity) | 3.56M | 11.35% | $20.2M | -1% |
| Versant Venture Management, LLC | 2.66M | 8.47% | $15.1M | No change |
| BlackRock, Inc. | 2.29M | 7.31% | $13M | +16% |
| Squarepoint Ops LLC | 1.75M | 5.57% | $9.9M | +16% |
| Aberdeen Group plc | 1.55M | 4.94% | $8.8M | +34% |
| Millennium Management LLC | 1.51M | 4.81% | $8.6M | +74% |
| Vanguard Capital Management LLC | 1.10M | 3.50% | $6.2M | +5% |
| 72 Investment Holdings, LLC | 1.02M | 3.25% | $5.8M | No change |
| Blue Owl Capital Holdings LP | 756,722 | 2.41% | $4.3M | +49% |
| C WorldWide Group Holding A/S | 700,000 | 2.23% | $4M | No change |
| Geode Capital Management, LLC | 564,662 | 1.80% | $3.2M | +8% |
| Trexquant Investment LP | 497,526 | 1.59% | $2.8M | +132% |
| Marshall Wace, LLP | 493,099 | 1.57% | $2.8M | +208% |
| Qube Research & Technologies Ltd | 482,195 | 1.54% | $2.7M | – |
| Morgan Stanley | 472,995 | 1.51% | $2.7M | -27% |
| Primecap Management Co | 472,200 | 1.51% | $2.7M | No change |
| Tang Capital Management LLC | 451,114 | 1.44% | $2.6M | No change |
| Alyeska Investment Group, L.P. | 438,882 | 1.40% | $2.5M | -5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LENZ insiders reported $366K of open-market purchases and $9.4M of sales. 3% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 2.16M | $3.36 | $7.3M | Form 4 |
| Oct 29, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 451,998 | $3.36 | $1.5M | Form 4 |
| Oct 29, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 107,170 | $3.36 | $360K | Form 4 |
| Mar 27, 2026 | Jeffrey P. George | Director | Purchase | 5,592 | $8.92 | $49.9K | Form 4 |
| Mar 27, 2026 | Evert B. Schimmelpennink | CEO | Purchase | 28,089 | $8.95 | $251K | Form 4 |
| Mar 27, 2026 | Daniel R. Chevallard | CFO | Purchase | 7,500 | $8.57 | $64.3K | Form 4 |
| Nov 17, 2025 | Shawn Olsson | Chief Commercial Officer | Sale plan | 4,212 | $25.74 | $108K | Form 4 |
| Nov 17, 2025 | Shawn Olsson | Chief Commercial Officer | Sale plan | 5,788 | $26.37 | $153K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10% owner | – | $9.1M | Oct 29, 2026 |
| Shawn Olsson | Chief Commercial Officer | – | $261K | Nov 17, 2025 |
| Evert B. Schimmelpennink | President, CEO and Secretary, Director | $251K | – | Mar 27, 2026 |
| Daniel R. Chevallard | Chief Financial Officer | $64.3K | – | Mar 27, 2026 |
| Jeffrey P. George | Director | $49.9K | – | Mar 27, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LENZ short interest
Very high short interest. 22.5% of LENZ shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went down 36%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.07M LENZ shares were sold short, 22.5% of the shares outstanding, down 22.3% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.07M | 22.50% | -22% | 1.26M | 5.6 |
| Oct 15, 2026 | 9.10M | 28.95% | -14% | 769,879 | 11.8 |
| Sep 30, 2026 | 10.56M | 33.61% | -1% | 766,161 | 13.8 |
| Sep 15, 2026 | 10.63M | 33.83% | -2% | 730,396 | 14.6 |
| Aug 31, 2026 | 10.87M | 34.61% | -3% | 575,660 | 18.9 |
| Aug 14, 2026 | 11.20M | 35.63% | -1% | 893,320 | 12.5 |
| Jul 31, 2026 | 11.32M | 36.10% | -5% | 957,770 | 11.8 |
| Jul 15, 2026 | 11.86M | 37.83% | +14% | 1.13M | 10.5 |
| Jun 30, 2026 | 10.43M | 33.27% | +1% | 945,476 | 11.0 |
| Jun 15, 2026 | 10.38M | 33.10% | +1% | 510,916 | 20.3 |
| May 29, 2026 | 10.23M | 32.63% | -8% | 809,814 | 12.6 |
| May 15, 2026 | 11.10M | 35.39% | +3% | 1.01M | 11.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
LENZ Therapeutics company events
LENZ Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 28, 2026.
- Oct 28, 2026LeadershipThe Company announced that Evert Schimmelpennink, the Company’s President and Chief Executive Officer, will transition from his roles as President and CEO effective December 1, 2026, with Daniel Chevallard, the Company’s current Chief Financial Officer, to succeed him as Interim President and CEO… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 2, 2026LeadershipZach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation of his resignation as a member of the Company’s Board of Directors and from all committees of the Board on which he served, effective immediately. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Jan 7, 2026ResultsReleased financial results. Filing
- Dec 12, 2025AnnouncementLENZ Therapeutics, Inc. is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration’s Adverse Event Reporting System database describing a retinal tear in a patient using VIZZ™ (aceclidine ophthalmic solution) 1.44%. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
LENZ Therapeutics financials
Famous investors that hold LENZ
3 of the 50 well-known investors we track reported holding LENZ in their latest 13F filing. The largest position is Israel Englander's, worth $4.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.16M | $4.5M | 0.0% | -23% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 181,788 | $698K | 0.0% | +157% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 95,325 | $366K | 0.0% | -74% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named LENZ in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 2.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 2.0% |
| Nov 4, 2026 | BML Investment Partners, L.P. | 13G | 6.7% |
| Nov 4, 2026 | BML Investment Partners, L.P. | 13G | 6.7% |
| Nov 2, 2026 | RA Capital Management, L.P. | 13D/A | 0.2% |
| Nov 2, 2026 | RA Capital Management, L.P. | 13D/A | 0.2% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.2% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.2% |
| Oct 21, 2026 | Millennium Management LLC | 13G/A | 3.7% |
| Oct 21, 2026 | Millennium Management LLC | 13G/A | 3.7% |
Questions about LENZ Therapeutics, Inc. (LENZ) stock
Who owns the most LENZ stock?
The largest reported owner of LENZ Therapeutics, Inc. (LENZ) is Ra Capital Management, L.P., with 13.3% of the company. In total, 144 funds and institutions reported holding LENZ at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are LENZ insiders buying or selling?
In the last 12 months, LENZ insiders reported 3 open-market purchases worth $366K and 5 sales worth $9.4M. The latest trade was on Oct 29, 2026. See every trade.
What is the short interest in LENZ?
As of Oct 30, 2026, 7.07M LENZ shares were sold short, 22.5% of the shares outstanding, down 22.3% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.6 trading days (days to cover). See the history.
Which famous investors hold LENZ?
3 of the 50 well-known investors we track reported LENZ in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $4.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.